Adlai Nortye Ltd. (NASDAQ:ANL – Get Free Report) was the recipient of a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 13,000 shares, an increase of 21.5% from the May 31st total of 10,700 shares. Based on an average trading volume of 16,500 shares, the days-to-cover ratio is presently 0.8 days.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Adlai Nortye in a research note on Thursday, June 20th.
Read Our Latest Analysis on Adlai Nortye
Institutional Trading of Adlai Nortye
Adlai Nortye Stock Up 11.5 %
NASDAQ:ANL traded up $0.37 during trading hours on Tuesday, reaching $3.64. 18,524 shares of the company’s stock were exchanged, compared to its average volume of 10,983. The company has a 50-day moving average of $8.63 and a 200 day moving average of $8.88. Adlai Nortye has a 1-year low of $3.04 and a 1-year high of $19.30.
Adlai Nortye Company Profile
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Read More
- Five stocks we like better than Adlai Nortye
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- RXO Shares Surge Following New Acquisition Deal
- How to Find Undervalued Stocks
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Insider Trades May Not Tell You What You Think
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.